Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I’m talking about after they stop…
I thought that was pretty obvious.
It works like it’s supposed to while taking it, and your body adapts to it just like anything else. (Edit: well, there’s chronic fatigue, vomiting, vertigo, all sorts of shit, but people on it already know about that, and you should get warned before starting. What people don’t get warned about is after stopping. So that’s what I’m focusing on)
And when you stop your body doesn’t have what it’s used to, don’t forget this is a medicine for diabetes, it will change how your body regulates blood sugar, and without it, it’s not going to know what the fuck to do
https://medicine.washu.edu/news/stopping-glp-1-drugs-can-quickly-erase-cardiovascular-benefits/
That talks about cardiovascular issues, but again, remember that while this passed trials for diabetes treatment, there hasn’t been many long term studies about what happens to people who stop taking it. And as time goes on, more people that need it less try it.
All the studies are at ~2 years out after cessation, and those were the people who were seriously obese. The people who started later and just “chubby” are likely to see diminished gains, but the same damage. Damage that we have no reason to believe will stop accumulating after 2 years…
That’s just as far as we’ve studied, all this shit should have done before released to the public.
yea, but… $$$$$$$$